Identity
Apelin is not a single molecule but a family of peptides cleaved from a 77-amino-acid precursor (preproapelin, gene APLN). Proteolytic processing yields apelin-36, apelin-17 (also called K17F), apelin-13 and the pyroglutamated form (Pyr1)apelin-13, which has the highest affinity for the receptor and is the predominant isoform found in human plasma. The C-terminal 17 residues are strictly conserved across every mammalian species studied — a strong sign of functional importance.
Its receptor, APJ (now formally the apelin receptor), is a seven-transmembrane G-protein-coupled receptor discovered in 1993 as an orphan, notable for sharing roughly 31% homology with the human angiotensin II receptor. That kinship is not incidental: the apelin system acts in several respects as a physiological counterweight to angiotensin II. A second endogenous APJ ligand, ELABELA (ELA), was identified later and shares much of the same biology.
Development & history
- 1993: O'Dowd and colleagues identify the orphan receptor APJ on chromosome 11, noting its similarity to the angiotensin receptor (Gene).
- 1998: Tatemoto et al. isolate apelin as the endogenous ligand, de-orphaning APJ (BBRC).
- 2000s: Preclinical cardiovascular characterisation — apelin increases contractility in isolated cardiomyocytes, ex vivo hearts and intact animals; plasma apelin is found to be reduced in heart failure patients, suggesting a deficit that might be worth correcting.
- 2010: Japp et al. publish the pivotal human study (Circulation): acute apelin infusion in healthy volunteers and in heart failure patients on standard therapy produces peripheral and coronary vasodilatation and raises cardiac output. APJ becomes a mainstream cardiovascular target.
- 2010s: The pharmacokinetic problem dominates. Native apelin's half-life of seconds to minutes rules out conventional dosing, so effort shifts to metabolically stabilised analogs — Novartis's cyclic apelin-13 analog CLR325 entered study in chronic stable heart failure (NCT02696967) — and to orally bioavailable small-molecule APJ agonists, of which BMS-986224 is the best-characterised preclinically.
- 2020s: Work continues on stabilised peptides such as LIT01-196 (an apelin-17 analog reducing cardiac dysfunction and remodelling post-infarction in animals, and normalising blood pressure in hypertensive rats via a nitric-oxide-dependent mechanism), CNS-penetrant APJ agonists, and industry APJ programmes. Reviews in 2025-2026 explore apelin/APJ as complementary to GLP-1 receptor agonist therapy in heart failure. Still no approval.
Mechanism (as proposed)
Apelin binding to APJ produces two therapeutically interesting effects through different cell types. In cardiomyocytes, APJ activation improves contractility via Gi/Gq, phospholipase C and calcium handling, and confers cardioprotection through Akt signalling — importantly, without raising cAMP, which distinguishes it from classic inotropes whose cAMP elevation is associated with arrhythmia and long-term harm. In endothelial cells, APJ agonism causes arterial vasodilatation, reducing the load the left ventricle works against.
The system is also woven into blood pressure and fluid regulation. Apelin opposes angiotensin II — partly by upregulating ACE2 (which degrades Ang II), partly through APJ–AT1R heterodimerisation that reduces AT1R availability — and interacts with vasopressin in water balance. This is why apelin biology reaches into hypertension and hyponatraemia as well as heart failure, and equally why casual administration in someone on cardiovascular medication is not a neutral act.
Reading the evidence honestly
Apelin sits in an unusual position: better human evidence than most research peptides, and a clearer reason it cannot be used as one.
The human finding is real. Acute apelin infusion measurably improves cardiac output and dilates coronary and peripheral vessels, in patients as well as healthy volunteers, on top of existing therapy. That is a stronger human result than most compounds in this register can point to, and it is why serious pharmaceutical programmes exist.
The pharmacokinetics are the story. A half-life of seconds to minutes means those results describe a continuous infusion under monitoring. This is not a formulation detail to be optimised around by a consumer — it is the reason every developer abandoned the native peptide for stabilised analogs and oral small molecules. Anything sold as "apelin" for self-administration cannot reproduce the studies used to sell it, and the mismatch is not marginal.
Haemodynamic improvement is not outcome improvement. Cardiovascular medicine has a long list of agents that raised cardiac output impressively and shortened lives. Until an APJ agonist completes an outcome trial, the honest position is that the target is promising and unproven — which is exactly what the ongoing analog programmes are trying to resolve.
The overall grade reflects this split: strong mechanism, strong acute human pharmacodynamics, credible drug target — and zero evidence supporting apelin itself as something to take.